Merck & Co., Inc. (MRK)
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works.
Merck: An Undervalued Dividend Machine
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the oncology drugs industry, which is expected to observe a 6.7% CAGR over the next five years. Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment appeal.
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion and $1.50, respectively.
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound.
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.
Is Merck Stock a Buy?
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript
Start Time: 09:00 January 1, 0000 10:00 AM ET Merck & Co., Inc. (NYSE:MRK ) Q3 2024 Earnings Call October 31, 2024, 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Shibutani - Goldman Sachs Daina Graybosch - Leerink Partners Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Trung Huynh - UBS Louise Chen - Cantor Carter Gould - Barclays Umer Raffat - Evercore ISI Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Operator Thank you for standing by. Welcome to the Merck & Company Q3 Sales and Earnings Conference Call.
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.
Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merck (MRK) Q3 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago.
Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year
Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business, the company's drug pipeline outlook, and more.
Merck tops estimates despite muted Gardasil and diabetes drug sales
Merck & Co Inc (NYSE:MRK, ETR:6MK) has topped third-quarter estimates despite flagging sales of its Gardasil jab, diabetes drugs and Covid-19 treatment. Revenue for the three months to September climbed by 4% to $16.66 billion, the pharmaceutical firm reported on Thursday, ahead of market expectations for $16.46 billion.
